# Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis.

*biotech · news · 2026-04-24 · The Manila Times*

## Key points

- CHMP has recommended EU approval of Sanofi’s Cenrifki (tolebrutinib) for non-relapsing SPMS.
- The HERCULES phase 3 study showed Cenrifki significantly delayed disability progression in non-relapsing SPMS.
- Safety data identifies drug-induced liver injury as a known risk of Cenrifki requiring strict liver monitoring.
- Cenrifki targets smoldering neuroinflammation, a key driver of disability in secondary progressive MS.
- Cenrifki submissions are under review with regulatory authorities in multiple countries beyond the EU.

**Companies:** Sanofi
**Countries:** France, EU

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/24/tmt-newswire/globenewswire/press-release-sanofis-cenrifki-tolebrutinib-recommended-for-eu-approval-by-the-chmp-to-treat-secondary-progressive-multiple-sclerosis-without-relapses/2327904)

---

Canonical: https://newsio.io/n/86fbf28e-c974-4763-973b-6aaa902919c0/sanofis-cenrifki-tolebrutinib-recommended-for-eu-approval-by-the-chmp-to-treat-s
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works